Frontiers in Pharmacology | Gastrointestinal and Hepatic Pharmacology

Original Research

Published on 24 Jan 2025

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database

in Gastrointestinal and Hepatic Pharmacology

Yuwei Liu
Xu Zhao
Xinrui Wang
Qiang Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1534628

257 views

Review

Published on 24 Jan 2025

Recent advances in polymeric nanoparticles for the treatment of hepatic diseases

in Gastrointestinal and Hepatic Pharmacology

Feng Gao
Xuefei Feng
Xinyu Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1528752

193 views

Review

Published on 23 Jan 2025

Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease

in Gastrointestinal and Hepatic Pharmacology

Wei Xuan
Dandan Song
Jianghua Hou
Xiuping Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1505117

161 views

Original Research

Accepted on 20 Jan 2025

Rutaecarpine Alleviates Hepatic Ischemia-reperfusion Injury in Liver Transplantation by Inhibiting Inflammatory Response and Oxidative Stress

in Gastrointestinal and Hepatic Pharmacology

Yan Liu
Feng Qi
Lun-Jian Xiang
Zhujun Yi
Shengwei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1539744

Original Research

Published on 20 Jan 2025

Cynaroside ameliorates TNBS-induced colitis by inhibiting intestinal epithelial cell apoptosis via the PI3K/AKT signalling pathway

in Gastrointestinal and Hepatic Pharmacology

Ju Huang
Jing Li
Zhijun Geng
Lixia Yin
Minzhu Niu
Qingqing Li
Xinyue Liu
Xinke Cheng
Xiaofeng Zhang
Xue Song

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1496068

245 views

Original Research

Published on 20 Jan 2025

Enhanced antitumor efficacy through sustained release of 5-fluorouracil from poly(trimethylene carbonate) membranes

in Gastrointestinal and Hepatic Pharmacology

Zongheng Wang
Zhipeng Hou
Shuguang Zhang
Shuangyi Ren
Liqun Yang
Qianshi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1536764

276 views

Original Research

Accepted on 17 Jan 2025

Epigallocatechin-3-gallate inhibits the collagen accumulation of oral submucous fibrosis induced by arecoline

in Gastrointestinal and Hepatic Pharmacology

Ge Gao
Caipeng Lin
Ruibo Li
Xi Xie
Hai-Bin Luo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1540559

Original Research

Published on 14 Jan 2025

Polydatin protects against DSS-induced ulcerative colitis via Nrf2/Slc7a11/Gpx4-dependent inhibition of ferroptosis signalling activation

in Gastrointestinal and Hepatic Pharmacology

Shimin Zheng
Jianbin Yin
Bingbing Wang
Qiujuan Ye
Jialuo Huang
Xinzhi Liang
Junfeng Wu
Hui Yue
Ting Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1513020

321 views

Systematic Review

Published on 09 Jan 2025

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease

in Gastrointestinal and Hepatic Pharmacology

Haohang Su
Shengwei Xiao
Zhiqing Liang
Tianrong Xun
Jinfang Zhang
Xixiao Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1475222

436 views

Review

Published on 09 Jan 2025

Functions of METTL1/WDR4 and QKI as m7G modification - related enzymes in digestive diseases

in Gastrointestinal and Hepatic Pharmacology

Wenyan Zhou
Yan Yi
Wenyu Cao
Xiaolin Zhong
Ling Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1491763

247 views

Correction

Accepted on 08 Jan 2025

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

in Gastrointestinal and Hepatic Pharmacology

Ting Li
Ting Fang
Linxin Xu
Xiangyang Liu
Xiaoyu Li
Mei Xue
Xiaochen Yu
Bei Sun
Liming Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1478437

Original Research

Accepted on 08 Jan 2025

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice

in Gastrointestinal and Hepatic Pharmacology

Xue-Ying Zhang
Qing-Qing Lu
Yan-Jie Li
Shan-Rui Shi
Chao-Nan Ma
Miao Miao
Shoudong Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1528250

Original Research

Published on 08 Jan 2025

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database

in Gastrointestinal and Hepatic Pharmacology

Qian Qiao
Jiachen Sun
Ya Zheng
Yingying Mi
Yanan Gong
Jiahui Liu
Wenyue Rui
Yumei Ma
Yongning Zhou
Min Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1507196

286 views

Original Research

Published on 08 Jan 2025

Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends

in Gastrointestinal and Hepatic Pharmacology

Hong-Yu Jiang
Bo Shao
Hong-Da Wang
Wen-Qi Zhao
Shao-Hua Ren
Yi-Ni Xu
Tong Liu
Cheng-Lu Sun
Yi-Yi Xiao
Yi-Cheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1523052

409 views

Original Research

Published on 07 Jan 2025

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis

in Gastrointestinal and Hepatic Pharmacology

Zhonghua Zhao
Xiongying Jiang
Shiping Wen
Yanzhang Hao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1499269

257 views

Original Research

Published on 07 Jan 2025

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database

in Gastrointestinal and Hepatic Pharmacology

Bojing Wang
Shu Huang
Shiqi Li
Yaqi Deng
Ziyan Li
Yizhou Wang
Xiaomin Shi
Wei Zhang
Lei Shi
Xiaohong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1502791

307 views

Navigation group

Articles

Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database

Recent advances in polymeric nanoparticles for the treatment of hepatic diseases

Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease

Rutaecarpine Alleviates Hepatic Ischemia-reperfusion Injury in Liver Transplantation by Inhibiting Inflammatory Response and Oxidative Stress

Cynaroside ameliorates TNBS-induced colitis by inhibiting intestinal epithelial cell apoptosis via the PI3K/AKT signalling pathway

Enhanced antitumor efficacy through sustained release of 5-fluorouracil from poly(trimethylene carbonate) membranes

Epigallocatechin-3-gallate inhibits the collagen accumulation of oral submucous fibrosis induced by arecoline

Polydatin protects against DSS-induced ulcerative colitis via Nrf2/Slc7a11/Gpx4-dependent inhibition of ferroptosis signalling activation

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease

Functions of METTL1/WDR4 and QKI as m7G modification - related enzymes in digestive diseases

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database

Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database